Interviews

Gilead execs Jared Baeten and Tomas Cihlar talk to Scrip about how the company, still the leader in HIV, is working toward less-frequent dosing, providing PrEP for broader populations and maybe finding a cure for HIV infection.

Emerging Company Profile: The French firm, which is developing the lead CTP synthase 1 inhibitor in the pipeline, plans to address a range of cancers with its highly selective approach.

CEO John Glasspool spoke with Scrip about why Anthos believes it has a good shot against big competitors in a market that is expected to generate blockbuster sales across multiple products.

Emerging Company Profile: The French biotech is developing a constrained peptide that targets an interaction in body fat tissue in the hopes of treating type 2 diabetes.

Having banked a $100m upfront fee from licensing partner Shionogi a couple of months ago, F2G has now unveiled a $70m financing to advance its late-stage novel oral antifungal, olorofim.

Data is the new gold and Timmo Rousku Andersen, Boehringer Ingelheim’s corporate senior vice-president, head of global regions, outlines in an interview the German group's efforts to shape go-to-market models driven by data and insights. He also touches on digital therapeutics and how the firm’s R&D engine is pursuing deeper insights into interconnected disorders.

Founder CEO Sanjay Singh tells Scrip about Gennova Biopharma's preliminary talks with investors looking to grab a piece of the action post approval of its mRNA vaccine against COVID-19. As the company considers use of the technology in making vaccines against cancer and infectious diseases, it will also expand manufacturing

Yuhan’s chief scientific officer shares why the leading Korean pharma firm is stepping up its open innovation activities and how this is helping to transform the company into a more global and R&D-based enterprise.

Emerging company profile: The US biotech is wrapping up a Phase I trial for its lead pancreatic cancer program at the end of this year and hopes to expand its precision drug-device combination platform to a range of other solid tumors.

David Peacock, President, Asia Pacific, MSD tells Scrip how Lagevrio has gained dominance in certain parts of the world, though Paxlovid may have received the ‘lion’s share’ of public attention.

CEO Pierre Belichard tells Scrip that the French biotech has enough cash and assets to prosper alone but it is also weighing up a reverse merger that would give Enterome a listing on the NASDAQ.

Barbara Lueckel, head of research technologies partnering, said Roche’s approach to platform deals has evolved with a focus on “generational technologies” to answer tough scientific questions.